Upregulation of Cereblon Expression By the DNA Methyltransferase Inhibitor Azacytidine Strongly Enhances Lenalidomide Cytotoxicity in Germinal Center B-Cell-like (GCB) and Activated B-Cell-like (ABC) Diffuse Large B-Cell Lymphoma (DLBCL)

MLA

Ada Koschorke, et al. “Upregulation of Cereblon Expression By the DNA Methyltransferase Inhibitor Azacytidine Strongly Enhances Lenalidomide Cytotoxicity in Germinal Center B-Cell-like (GCB) and Activated B-Cell-like (ABC) Diffuse Large B-Cell Lymphoma (DLBCL).” Blood, vol. 124, Dec. 2014, p. 2253. EBSCOhost, https://doi.org/10.1182/blood.v124.21.2253.2253.

APA

Ada Koschorke, Monica Balzarotti, Silvia L. Locatelli, Carmelo Carlo-Stella, Armando Santoro, Luca Castagna, Giuliano G Stirparo, Roberto Papait, & Giuseppa Careddu. (2014). Upregulation of Cereblon Expression By the DNA Methyltransferase Inhibitor Azacytidine Strongly Enhances Lenalidomide Cytotoxicity in Germinal Center B-Cell-like (GCB) and Activated B-Cell-like (ABC) Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 124, 2253. https://doi.org/10.1182/blood.v124.21.2253.2253

Chicago

Ada Koschorke, Monica Balzarotti, Silvia L. Locatelli, Carmelo Carlo-Stella, Armando Santoro, Luca Castagna, Giuliano G Stirparo, Roberto Papait, and Giuseppa Careddu. 2014. “Upregulation of Cereblon Expression By the DNA Methyltransferase Inhibitor Azacytidine Strongly Enhances Lenalidomide Cytotoxicity in Germinal Center B-Cell-like (GCB) and Activated B-Cell-like (ABC) Diffuse Large B-Cell Lymphoma (DLBCL).” Blood 124 (December): 2253. doi:10.1182/blood.v124.21.2253.2253.